Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain

Lars Arendt-Nielsen, Søren Thorgaard Skou, Thomas A Nielsen, Kristian K Petersen

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Musculoskeletal pain disorders are the second largest contributor to global disability underlining the significance of effective treatments. However, treating chronic musculoskeletal pain, and chronic joint pain (osteoarthritis (OA)) in particular, is challenging as the underlying peripheral and central pain mechanisms are not fully understood, and safe and efficient analgesic drugs are not available. The pain associated with joint pain is highly individual, and features from radiological imaging have not demonstrated robust associations with the pain manifestations. In recent years, a variety of human quantitative pain assessment tools (quantitative sensory testing (QST)) have been developed providing new opportunities for profiling patients and reaching a greater understanding of the mechanisms involved in chronic joint pain. As joint pain is a complex interaction between many different pain mechanisms, available tools are important for patent profiling and providing the basic knowledge for development of new drugs and for developing pain management regimes.

Original languageEnglish
JournalCurrent Osteoporosis Reports (Print)
Volume13
Issue number4
Pages (from-to)225-234
ISSN1544-1873
DOIs
Publication statusPublished - Aug 2015

Fingerprint

Central Nervous System Sensitization
Chronic Pain
Pain Measurement
Pain Management
Pharmaceutical Preparations

Cite this

Arendt-Nielsen, Lars ; Skou, Søren Thorgaard ; Nielsen, Thomas A ; Petersen, Kristian K. / Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain. In: Current Osteoporosis Reports (Print). 2015 ; Vol. 13 , No. 4. pp. 225-234.
@article{c37acf33e5374f2fa69d563c8b73636f,
title = "Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain",
abstract = "Musculoskeletal pain disorders are the second largest contributor to global disability underlining the significance of effective treatments. However, treating chronic musculoskeletal pain, and chronic joint pain (osteoarthritis (OA)) in particular, is challenging as the underlying peripheral and central pain mechanisms are not fully understood, and safe and efficient analgesic drugs are not available. The pain associated with joint pain is highly individual, and features from radiological imaging have not demonstrated robust associations with the pain manifestations. In recent years, a variety of human quantitative pain assessment tools (quantitative sensory testing (QST)) have been developed providing new opportunities for profiling patients and reaching a greater understanding of the mechanisms involved in chronic joint pain. As joint pain is a complex interaction between many different pain mechanisms, available tools are important for patent profiling and providing the basic knowledge for development of new drugs and for developing pain management regimes.",
author = "Lars Arendt-Nielsen and Skou, {S{\o}ren Thorgaard} and Nielsen, {Thomas A} and Petersen, {Kristian K}",
year = "2015",
month = "8",
doi = "10.1007/s11914-015-0276-x",
language = "English",
volume = "13",
pages = "225--234",
journal = "Current Osteoporosis Reports (Print)",
issn = "1544-1873",
publisher = "Current Science Inc.",
number = "4",

}

Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain. / Arendt-Nielsen, Lars; Skou, Søren Thorgaard; Nielsen, Thomas A; Petersen, Kristian K.

In: Current Osteoporosis Reports (Print), Vol. 13 , No. 4, 08.2015, p. 225-234.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Altered Central Sensitization and Pain Modulation in the CNS in Chronic Joint Pain

AU - Arendt-Nielsen, Lars

AU - Skou, Søren Thorgaard

AU - Nielsen, Thomas A

AU - Petersen, Kristian K

PY - 2015/8

Y1 - 2015/8

N2 - Musculoskeletal pain disorders are the second largest contributor to global disability underlining the significance of effective treatments. However, treating chronic musculoskeletal pain, and chronic joint pain (osteoarthritis (OA)) in particular, is challenging as the underlying peripheral and central pain mechanisms are not fully understood, and safe and efficient analgesic drugs are not available. The pain associated with joint pain is highly individual, and features from radiological imaging have not demonstrated robust associations with the pain manifestations. In recent years, a variety of human quantitative pain assessment tools (quantitative sensory testing (QST)) have been developed providing new opportunities for profiling patients and reaching a greater understanding of the mechanisms involved in chronic joint pain. As joint pain is a complex interaction between many different pain mechanisms, available tools are important for patent profiling and providing the basic knowledge for development of new drugs and for developing pain management regimes.

AB - Musculoskeletal pain disorders are the second largest contributor to global disability underlining the significance of effective treatments. However, treating chronic musculoskeletal pain, and chronic joint pain (osteoarthritis (OA)) in particular, is challenging as the underlying peripheral and central pain mechanisms are not fully understood, and safe and efficient analgesic drugs are not available. The pain associated with joint pain is highly individual, and features from radiological imaging have not demonstrated robust associations with the pain manifestations. In recent years, a variety of human quantitative pain assessment tools (quantitative sensory testing (QST)) have been developed providing new opportunities for profiling patients and reaching a greater understanding of the mechanisms involved in chronic joint pain. As joint pain is a complex interaction between many different pain mechanisms, available tools are important for patent profiling and providing the basic knowledge for development of new drugs and for developing pain management regimes.

U2 - 10.1007/s11914-015-0276-x

DO - 10.1007/s11914-015-0276-x

M3 - Journal article

C2 - 26026770

VL - 13

SP - 225

EP - 234

JO - Current Osteoporosis Reports (Print)

JF - Current Osteoporosis Reports (Print)

SN - 1544-1873

IS - 4

ER -